Pharming Group

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. The Company’s products are aimed at treatments for genetic disorders and surgical and traumatic bleeding. Pharming’s technologies include novel transgenic platforms for the production of biopharmaceuticals, as well as technology and processes for the purification and formulation of these biopharmaceuticals. The Company’s commercial partners are: Santarus, Sobi, MegaPharm, Eczacibasi, Transmedic and Hyupjin. The Company operates worldwide. In March 2014, it announced downsizing of the Dutch operations following from strategic re-emphasis on collaborative development efforts and out-sourcing of non-core activities.

Company Growth (employees)
Type
Public
HQ
Leiden, NL
Founded
1988
Size (employees)
94 (est)+19%
Pharming Group was founded in 1988 and is headquartered in Leiden, NL

Pharming Group Office Locations

Pharming Group has an office in Leiden
Leiden, NL (HQ)
24 Darwinweg

Pharming Group Data and Metrics

Pharming Group Financial Metrics

EUR

Market capitalization (19-Sep-2017)

286.2 m

Closing share price (19-Sep-2017)

0.6
Pharming Group's current market capitalization is €286.2 m.
Show all financial metrics

Pharming Group Market Value History

Traffic Overview of Pharming Group

Pharming Group News and Updates

Valeant Outlines Asset Sale Plan to Cut Debt, Stock Jumps

Valeant Pharmaceuticals International Inc will sell billions of dollars in assets to pay down debt and focus on businesses like dermatology and Bausch & Lomb eyecare, the Canadian drug maker said on Tuesday, driving its shares up 13 percent.

Valeant outlines asset sale plan to cut debt, stock jumps

(Reuters) - Valeant Pharmaceuticals International Inc will sell billions of dollars in assets to pay down debt and focus on businesses like dermatology and Bausch & Lomb eyecare, the Canadian drug maker said on Tuesday, driving its shares up 13 percent.

UPDATE 3-Valeant outlines asset sale plan to cut debt, stock jumps

Aug 9 (Reuters) - Valeant Pharmaceuticals International Inc will sell billions of dollars in assets to pay down debt and focus on businesses like dermatology and Bausch & Lomb eyecare, the Canadian drug maker said on Tuesday, driving its shares up 13 percent.

Here’s Why Shares of Valeant Are Jumping

Despite a drop in revenue

Pharming Group Company Life and Culture

You may also be interested in